biotech investing BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
biotech investing BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
biotech investing BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
pharmaceutical investing Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
pharmaceutical investing BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
pharmaceutical investing BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+
pharmaceutical investing BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer
pharmaceutical investing BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer
pharmaceutical investing BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT
pharmaceutical investing BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT
pharmaceutical investing BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT